Skip to main content
. Author manuscript; available in PMC: 2022 Apr 12.
Published in final edited form as: Lancet Oncol. 2015 Jun 23;16(8):908–918. doi: 10.1016/S1470-2045(15)00083-2

Figure 3: Prespecified subgroup analysis of progression-free survival.

Figure 3:

Progression-free survival assessed by RECIST v1.1, by independent central review in the intention-to-treat population; pembrolizumab 2 mg/kg versus chemotherapy (A) and pembrolizumab 10 mg/kg versus chemotherapy (B). HR=hazard ratio. ECOG PS=Eastern Cooperative Oncology Group performance status. LDH=lactate dehydrogenase.